Sabitlenmiş Tweet
Ibrahim Azar, MD
1.5K posts
Ibrahim Azar, MD
@ibrahimazaronc
Medical Oncologist @IHACares Assistant Professor @WayneState. Alum @karmanoscancer @AlbanyMed @mcgillu. AΩA. GI Oncology Mednet Associate Editor.
Katılım Aralık 2018
988 Takip Edilen946 Takipçiler
Ibrahim Azar, MD retweetledi
In an evaluation in low- and middle-income countries involving 95 patients with chronic myeloid leukemia who had deep remission for more than 1 year, 79% remained in treatment-free remission after imatinib discontinuation. Learn more: nejm.org/doi/full/10.10…
English
@dr_yakupergun Most worrisome is the reviewer invites you get for something you have never published or are familiar with. Its because no one wants to review for free and the articles sit for ages waiting for reviewers
English
I’ve been getting a lot of reviewer invitations lately.
The “benefits” section was particularly elegant: “You will have a front-row seat to ideas shaping your field.
The journal will charge the author 3,150 CHF APC, and I’ll get the privilege of seeing the manuscript early 🤓
English
Ibrahim Azar, MD retweetledi
Ibrahim Azar, MD retweetledi
1/n
Setidegrasib the first-in-human, first-in-class, KRAS G12D-targeted protein degrader #TPD
Our KRAS G12D degrader study is now published in the New England Journal of Medicine @NEJM
nejm.org/doi/full/10.10…
A new way to target KRAS G12D - one of the most common oncogenic drivers across cancers.
Guadalupe, AZ 🇺🇸 English
Ibrahim Azar, MD retweetledi
Among men with locally advanced prostate cancer, transdermal estradiol was noninferior to LHRH agonists for 3-year metastasis-free survival and led to a lower incidence of hot flashes but a higher incidence of gynecomastia. Full results of the STAMPEDE-1 and PATCH trials: nejm.org/doi/full/10.10…
English
@drsarahsam @dralpertopal @OncoAlert In a triple positive breast cancer with significant neoadjvusnt thp, would you ever start TDxD then switch to Patina ?
English
How I think about 1st line HER2+ Metastatic Breast Cancer.
Decision 1: THP versus T-DXd + P
Decision 2: Maintenance based on receptor status
@OncoAlert #bcsm
English
Ibrahim Azar, MD retweetledi
💙 March is Colorectal Cancer Awareness Month.
Dr. Fernand Bteich @fernandbteich @MontefioreNYC reviews evolving strategies for KRAS-mutated metastatic CRC, including advances in molecular testing, targeted therapies, and overcoming resistance.
🎥 Watch on #Vumedi: tinyurl.com/59j2ufnp
#ColorectalCancer #GIOncology #CancerAwareness #PrecisionOncology
English
Ibrahim Azar, MD retweetledi
In MD Anderson, we have treated all SBRT consecutive days including 54 Gy in 3 FX, 50 Gy (SIB GTV 60 Gy) in 4 Fx, 50 Gy (SIB GTV 60 Gy) in 5 Fx. We don’t observe any particular concerns for side effects and it is much convenient for our patients.
Drew Moghanaki@DrewMoghanaki
A Canadian study demonstrates that lung SBRT yields a similar success and safety profile when delivered on sequential versus every other day. Why? It’s likely because the rate of adverse events is minuscule in the first place. 🇨🇦 #Miniscule #radonc practicalradonc.org/article/S1879-…
English
Ibrahim Azar, MD retweetledi
Do we need to follow patients up who have had resection of node-negative typical lung carcinoid tumors (TC)?
According to this study of 290 patients with node-neg TC, only 4 had recurrence after a median f/u time of 8.1 years for a cumulative risk of recurrence of 3.4%.
Among the 4 patients, one had a curative-intent re-resection? How low is low recurrence risk for us not to follow up? I think an argument can be made not to follow patients with node-neg TC based on these results.
onlinelibrary.wiley.com/doi/10.1111/jn…
English
Ibrahim Azar, MD retweetledi
Even if physician and nursing salaries were eliminated entirely, the U.S. would still have the most expensive healthcare system by a wide margin.
TL;DR: U.S. healthcare costs are driven primarily by administrative overhead, insurance complexity, pharmaceuticals, and medical devices—not clinician salaries.
Ashish K. Jha@ashishkjha
If you're thinking about healthcare spending in the US, one fact worth noting About 9% of healthcare spending goes to physician compensation Another 9% goes to nurses Yes, doctors and nurses get paid more in the US than they do in other countries and yes, a small proportion of physicians really do get paid a lot But I've never thought we're going to solve our healthcare spending by going after physician and nursing salaries Not enough there -- and slashing physician or nursing compensation would be a great way to demoralize the core of the US healthcare workforce
English
Ibrahim Azar, MD retweetledi
A 240 pateint single arm trial exploring 9 cycles of EVP without planned surgery in MIBC. This will answer the key questions ‘What happens if we don’t do cystectomy in those with clinical complete response after initial EVP’.It assesses cCR rates and bladder intact EFS. It will clarify ‘EVP 1st ask questions later’ #GUtrendingTopics @OncoAlert
English
Ibrahim Azar, MD retweetledi
pCR after neoadjuvant chemotherapy has long been considered a strong prognostic marker.
But adding ultra-sensitive ctDNA changes the picture.
In the PREDICT-DNA trial (NeXT Personal @PersonalisInc ), ctDNA-negative patients among non-pCR cases showed outcomes comparable to pCR. @JCO_ASCO
Small sample size—but a highly impactful finding.
ascopubs.org/doi/10.1200/JC…
English
@rajshekharucms @Rfonsi1 @Tontarnnaja @bdermanmd @End_myeloma I'm no myeloma expert. Is there evidence that treating the MRD rising makes a difference in outcomes ?
English
@Rfonsi1 @Tontarnnaja @bdermanmd @End_myeloma Yeah, when I see such a clonoSEQ curve with >3 log increase in MRD over a short time, I am not even interested in what the biochemical markers are!
English
#Myeloma response assessment paradox: MRD resurgence on clonoSEQ (>3 logs). FLCs rising. But no "progression" — because they haven't crossed an arbitrary dFLC>10 mg/dL cutoff.
@bdermanmd @End_myeloma
English
@BijoyTelivala @OncBrothers @MyriamChalabi @FASinicropeMD @CathyEngMD @GIcancerDoc @manjuggm @dr_yakupergun @GIMedOnc @pashtoonkasi Exactly. The issue here you dont know what you're dealing with upfront
English
@OncBrothers @MyriamChalabi @FASinicropeMD @CathyEngMD @GIcancerDoc @manjuggm @dr_yakupergun @GIMedOnc @pashtoonkasi Might be a stupid question but how confident are we on ct and pet imaging to stage a tumor as T3 vs T4 and LN status for say ascending or transverse colon
90 % of radiologist don't put that in report and there is dramatic variance in those who put it in
English
For dMMR colon cancer, clinical Stage II (cT3-4N0 by imaging) do you rely on Ipi-Nivo upfront (NICHE-2) or Adj treatment (if upstaged per ATOMIC)?
#gism @MyriamChalabi @FASinicropeMD @BijoyTelivala @CathyEngMD @GIcancerDoc @manjuggm @dr_yakupergun @GIMedOnc @pashtoonkasi
English
Ibrahim Azar, MD retweetledi
@Papa_Heme still lots of mel140 autos despite evidence that it’s no better than rev maintenance, and that was in the pre dara era
ashpublications.org/blood/article/…
English
@JamesBarnesMD @MaxJordan_N The issue is the system made clinical work more burn-out prone. Physicians should see patients and not be in a system where they risk feeling burnout because they stick to it as opposed to admin/research/etc
English
@MaxJordan_N I’m happy that people do thing they want to , we need their help, but agree that if someone is burning out or wants to prevent it, would recommend going less than 1.0 fte clinical
English
All the ppl responding with how they work so much more as attendings than in training…. I’m sad for you because you… don’t have to. No one is making you. As a doctor you have so much control over how much you decide to work if you’re willing to give up some of the pay.
Max Jordan Nguemeni@MaxJordan_N
This is a lie told by people who want to exploit your labor. The main difference between now and residency, which has helped me feel so much better mentally and emotionally, is that I work a lot less!
English
@nativbklyn24 @SashaGusevPosts Probably chemoIO unfortunately
English
@SashaGusevPosts So what are they getting instead? erlotinib? No generic ALK inhibitors...
English
Ibrahim Azar, MD retweetledi
Since people are talking about cutting-edge cancer treatments, it is good to remember that in many states patients do not receive targeted therapies that they are approved for. There's a lot of alpha in getting healthcare in the US to look like it does in MA, HI, and NY.
English
@NiuSanford I've started holding IO before radiation, not beucase of side effects. But because of the negative studies with concurrent IO and Rt on lung cancer
English
Someone suggested I make a table summarizing the video. Here it is!
Dr. Nina Niu Sanford@NiuSanford
Have you ever wondered whether you need to hold systemic during RT due to concern for additive toxicity? See this 10 min video. Categorized by systemic type (cytoxic chemo, IO, TKI, BRAF, etc) & RT regimen (SBRT/conventional/palliative) Slides🧵& full video below. 1/8
English